Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 91


EC359: A First-in-Class Small-Molecule Inhibitor for Targeting Oncogenic LIFR Signaling in Triple-Negative Breast Cancer.

Viswanadhapalli S, Luo Y, Sareddy GR, Santhamma B, Zhou M, Li M, Ma S, Sonavane R, Pratap UP, Altwegg KA, Li X, Chang A, Chávez-Riveros A, Dileep KV, Zhang KYJ, Pan X, Murali R, Bajda M, Raj GV, Brenner AJ, Manthati V, Rao MK, Tekmal RR, Nair HB, Nickisch KJ, Vadlamudi RK.

Mol Cancer Ther. 2019 Aug;18(8):1341-1354. doi: 10.1158/1535-7163.MCT-18-1258. Epub 2019 May 29.


Estrogen receptor beta enhances chemotherapy response of GBM cells by down regulating DNA damage response pathways.

Zhou M, Sareddy GR, Li M, Liu J, Luo Y, Venkata PP, Viswanadhapalli S, Tekmal RR, Brenner A, Vadlamudi RK.

Sci Rep. 2019 Apr 16;9(1):6124. doi: 10.1038/s41598-019-42313-8.


Esters of levonorgestrel and etonogestrel intended as single, subcutaneous-injection, long-lasting contraceptives.

Meece FA, Ahmed G, Nair H, Santhamma B, Tekmal RR, Zhao C, Pollok NE, Lara J, Shaked Z, Nickisch K.

Steroids. 2018 Sep;137:47-56. doi: 10.1016/j.steroids.2018.07.010. Epub 2018 Aug 4.


Development and Evaluation of Talazoparib Nanoemulsion for Systemic Therapy of BRCA1-mutant Cancer.

Mehra NK, Tekmal RR, Palakurthi S.

Anticancer Res. 2018 Aug;38(8):4493-4503. doi: 10.21873/anticanres.12753.


Differential Effects of Estrogen Receptor β Isoforms on Glioblastoma Progression.

Liu J, Sareddy GR, Zhou M, Viswanadhapalli S, Li X, Lai Z, Tekmal RR, Brenner A, Vadlamudi RK.

Cancer Res. 2018 Jun 15;78(12):3176-3189. doi: 10.1158/0008-5472.CAN-17-3470. Epub 2018 Apr 16.


The Hyaluronic Acid System is Intact in Menstrual Endometrial Cells in Women With and Without Endometriosis.

Knudtson JF, McLaughlin JE, Santos MT, Binkley PA, Tekmal RR, Schenken RS.

Reprod Sci. 2019 Jan;26(1):109-113. doi: 10.1177/1933719118766257. Epub 2018 Apr 5.


Therapeutic Use of Estrogen Receptor β Agonists in Prevention and Treatment of Endocrine Therapy Resistant Breast Cancers: Observations From Preclinical Models.

Ramasamy K, Samayoa C, Krishnegowda N, Tekmal RR.

Prog Mol Biol Transl Sci. 2017;151:177-194. doi: 10.1016/bs.pmbts.2017.08.002. Epub 2017 Oct 6. Review.


Estrogen receptor coregulator binding modulators (ERXs) effectively target estrogen receptor positive human breast cancers.

Raj GV, Sareddy GR, Ma S, Lee TK, Viswanadhapalli S, Li R, Liu X, Murakami S, Chen CC, Lee WR, Mann M, Krishnan SR, Manandhar B, Gonugunta VK, Strand D, Tekmal RR, Ahn JM, Vadlamudi RK.

Elife. 2017 Aug 8;6. pii: e26857. doi: 10.7554/eLife.26857.


Clinical and Pathologic Features of Hispanic Endometrial Cancer Patients With Loss of Mismatch Repair Expression.

Kost ER, Valente PT, Lynch BA, Krishnegowda NK, Hertz AM, Hall KL, Riddle ND, Tekmal RR.

Int J Gynecol Cancer. 2016 Jul;26(6):1129-1136. doi: 10.1097/IGC.0000000000000713.


Clinical and Pathologic Features of Hispanic Endometrial Cancer Patients With Loss of Mismatch Repair Expression.

Kost ER, Valente PT, Lynch BA, Krishnegowda NK, Hertz AM, Hall KL, Riddle ND, Tekmal RR.

Int J Gynecol Cancer. 2016 Jul;26(6):1129-36. doi: 10.1097/IGC.0000000000000713.


Selective Estrogen Receptor β Agonist LY500307 as a Novel Therapeutic Agent for Glioblastoma.

Sareddy GR, Li X, Liu J, Viswanadhapalli S, Garcia L, Gruslova A, Cavazos D, Garcia M, Strom AM, Gustafsson JA, Tekmal RR, Brenner A, Vadlamudi RK.

Sci Rep. 2016 Apr 29;6:24185. doi: 10.1038/srep24185.


A Combination of a GnRH Antagonist and Agonist for Fertility Preservation in an Adolescent Female Murine Model.

Knudtson JF, Tellez Santos M, Failor CM, Binkley PA, Venesky JP, Tekmal RR, Robinson RD, Schenken RS.

Reprod Sci. 2017 Sep;24(9):1280-1283. doi: 10.1177/1933719116682876. Epub 2016 Dec 14.


Obesity Suppresses Estrogen Receptor Beta Expression in Breast Cancer Cells via a HER2-Mediated Pathway.

Bowers LW, Wiese M, Brenner AJ, Rossi EL, Tekmal RR, Hursting SD, deGraffenried LA.

PLoS One. 2015 Dec 28;10(12):e0145452. doi: 10.1371/journal.pone.0145452. eCollection 2015.


Impaired Development of Early Endometriotic Lesions in CD44 Knockout Mice.

Knudtson JF, Tekmal RR, Santos MT, Binkley PA, Krishnegowda N, Valente P, Schenken RS.

Reprod Sci. 2016 Jan;23(1):87-91. doi: 10.1177/1933719115594022. Epub 2015 Jul 12.


Aromatase expression increases the survival and malignancy of estrogen receptor positive breast cancer cells.

Mukhopadhyay KD, Liu Z, Bandyopadhyay A, Kirma NB, Tekmal RR, Wang S, Sun LZ.

PLoS One. 2015 Apr 2;10(4):e0121136. doi: 10.1371/journal.pone.0121136. eCollection 2015.


Obesity-associated systemic interleukin-6 promotes pre-adipocyte aromatase expression via increased breast cancer cell prostaglandin E2 production.

Bowers LW, Brenner AJ, Hursting SD, Tekmal RR, deGraffenried LA.

Breast Cancer Res Treat. 2015 Jan;149(1):49-57. doi: 10.1007/s10549-014-3223-0. Epub 2014 Dec 5.


PELP1 overexpression in the mouse mammary gland results in the development of hyperplasia and carcinoma.

Cortez V, Samayoa C, Zamora A, Martinez L, Tekmal RR, Vadlamudi RK.

Cancer Res. 2014 Dec 15;74(24):7395-405. doi: 10.1158/0008-5472.CAN-14-0993. Epub 2014 Nov 6.


NSAID use reduces breast cancer recurrence in overweight and obese women: role of prostaglandin-aromatase interactions.

Bowers LW, Maximo IX, Brenner AJ, Beeram M, Hursting SD, Price RS, Tekmal RR, Jolly CA, deGraffenried LA.

Cancer Res. 2014 Aug 15;74(16):4446-57. doi: 10.1158/0008-5472.CAN-13-3603.


A phosphotyrosine switch determines the antitumor activity of ERβ.

Yuan B, Cheng L, Chiang HC, Xu X, Han Y, Su H, Wang L, Zhang B, Lin J, Li X, Xie X, Wang T, Tekmal RR, Curiel TJ, Yuan ZM, Elledge R, Hu Y, Ye Q, Li R.

J Clin Invest. 2014 Aug;124(8):3378-90. doi: 10.1172/JCI74085. Epub 2014 Jun 24.


Proline, glutamic acid and leucine-rich protein-1 is essential for optimal p53-mediated DNA damage response.

Nair BC, Krishnan SR, Sareddy GR, Mann M, Xu B, Natarajan M, Hasty P, Brann D, Tekmal RR, Vadlamudi RK.

Cell Death Differ. 2014 Sep;21(9):1409-18. doi: 10.1038/cdd.2014.55. Epub 2014 May 2.


Effects of a novel proteasome inhibitor BU-32 on multiple myeloma cells.

Roy SS, Kirma NB, Santhamma B, Tekmal RR, Agyin JK.

Cancer Chemother Pharmacol. 2014 Jun;73(6):1263-71. doi: 10.1007/s00280-014-2463-3. Epub 2014 Apr 12.


Inhibition of mTOR signaling reduces PELP1-mediated tumor growth and therapy resistance.

Gonugunta VK, Sareddy GR, Krishnan SR, Cortez V, Roy SS, Tekmal RR, Vadlamudi RK.

Mol Cancer Ther. 2014 Jun;13(6):1578-88. doi: 10.1158/1535-7163.MCT-13-0877. Epub 2014 Mar 31.


Significance of PELP1/HDAC2/miR-200 regulatory network in EMT and metastasis of breast cancer.

Roy SS, Gonugunta VK, Bandyopadhyay A, Rao MK, Goodall GJ, Sun LZ, Tekmal RR, Vadlamudi RK.

Oncogene. 2014 Jul 10;33(28):3707-16. doi: 10.1038/onc.2013.332. Epub 2013 Aug 26.


Gossypin as a novel selective dual inhibitor of V-RAF murine sarcoma viral oncogene homolog B1 and cyclin-dependent kinase 4 for melanoma.

Bhaskaran S, Dileep KV, Deepa SS, Sadasivan C, Klausner M, Krishnegowda NK, Tekmal RR, VandeBerg JL, Nair HB.

Mol Cancer Ther. 2013 Apr;12(4):361-72. doi: 10.1158/1535-7163.MCT-12-0965. Epub 2013 Mar 29.


Raf-1, a potential therapeutic target, mediates early steps in endometriosis lesion development by endometrial epithelial and stromal cells.

De La Garza EM, Binkley PA, Ganapathy M, Krishnegowda NK, Tekmal RR, Schenken RS, Kirma NB.

Endocrinology. 2012 Aug;153(8):3911-21. doi: 10.1210/en.2011-1879. Epub 2012 May 22.


Therapeutic significance of estrogen receptor β agonists in gliomas.

Sareddy GR, Nair BC, Gonugunta VK, Zhang QG, Brenner A, Brann DW, Tekmal RR, Vadlamudi RK.

Mol Cancer Ther. 2012 May;11(5):1174-82. doi: 10.1158/1535-7163.MCT-11-0960. Epub 2012 Mar 21.


Increased expression of macrophage colony-stimulating factor and its receptor in patients with endometriosis.

Budrys NM, Nair HB, Liu YG, Kirma NB, Binkley PA, Kumar S, Schenken RS, Tekmal RR.

Fertil Steril. 2012 May;97(5):1129-35.e1. doi: 10.1016/j.fertnstert.2012.02.007. Epub 2012 Feb 24.


Transgenic mouse models of hormonal mammary carcinogenesis: advantages and limitations.

Kirma NB, Tekmal RR.

J Steroid Biochem Mol Biol. 2012 Sep;131(3-5):76-82. doi: 10.1016/j.jsbmb.2011.11.005. Epub 2011 Nov 17. Review.


Significance of PELP1 in ER-negative breast cancer metastasis.

Roy S, Chakravarty D, Cortez V, De Mukhopadhyay K, Bandyopadhyay A, Ahn JM, Raj GV, Tekmal RR, Sun L, Vadlamudi RK.

Mol Cancer Res. 2012 Jan;10(1):25-33. doi: 10.1158/1541-7786.MCR-11-0456. Epub 2011 Nov 15.


Estrogen receptor-beta mediates the protective effects of aromatase induction in the MMTV-Her-2/neu x aromatase double transgenic mice.

Nair HB, Perla RP, Kirma NB, Krishnegowda NK, Ganapathy M, Rajhans R, Nair SS, Saikumar P, Vadlamudi RK, Tekmal RR.

Horm Cancer. 2012 Apr;3(1-2):26-36. doi: 10.1007/s12672-011-0083-5.


Roscovitine confers tumor suppressive effect on therapy-resistant breast tumor cells.

Nair BC, Vallabhaneni S, Tekmal RR, Vadlamudi RK.

Breast Cancer Res. 2011 Aug 11;13(3):R80. doi: 10.1186/bcr2929.


Hyaluronic acid-bound letrozole nanoparticles restore sensitivity to letrozole-resistant xenograft tumors in mice.

Nair HB, Huffman S, Veerapaneni P, Kirma NB, Binkley P, Perla RP, Evans DB, Tekmal RR.

J Nanosci Nanotechnol. 2011 May;11(5):3789-99.


Modeling ductal carcinoma in situ: a HER2-Notch3 collaboration enables luminal filling.

Pradeep CR, Köstler WJ, Lauriola M, Granit RZ, Zhang F, Jacob-Hirsch J, Rechavi G, Nair HB, Hennessy BT, Gonzalez-Angulo AM, Tekmal RR, Ben-Porath I, Mills GB, Domany E, Yarden Y.

Oncogene. 2012 Feb 16;31(7):907-17. doi: 10.1038/onc.2011.279. Epub 2011 Jul 11.


Colony-stimulating factor-1 exerts direct effects on the proliferation and invasiveness of endometrial epithelial cells.

Aligeti S, Kirma NB, Binkley PA, Schenken RS, Tekmal RR.

Fertil Steril. 2011 Jun 30;95(8):2464-6. doi: 10.1016/j.fertnstert.2011.03.026. Epub 2011 Apr 9.


Estrogen receptor-β activation in combination with letrozole blocks the growth of breast cancer tumors resistant to letrozole therapy.

Nair HB, Kirma NB, Ganapathy M, Vadlamudi RK, Tekmal RR.

Steroids. 2011 Jul;76(8):792-6. doi: 10.1016/j.steroids.2011.02.038. Epub 2011 Apr 6.


Significance of ER-Src axis in hormonal therapy resistance.

Vallabhaneni S, Nair BC, Cortez V, Challa R, Chakravarty D, Tekmal RR, Vadlamudi RK.

Breast Cancer Res Treat. 2011 Nov;130(2):377-85. doi: 10.1007/s10549-010-1312-2. Epub 2010 Dec 24.


Cyclin-dependent kinase-mediated phosphorylation plays a critical role in the oncogenic functions of PELP1.

Nair BC, Nair SS, Chakravarty D, Challa R, Manavathi B, Yew PR, Kumar R, Tekmal RR, Vadlamudi RK.

Cancer Res. 2010 Sep 15;70(18):7166-75. doi: 10.1158/0008-5472.CAN-10-0628. Epub 2010 Aug 31.


Imatinib decreases endometrial stromal cell transmesothial migration and proliferation in the extracellular matrix of modeled peritoneum.

Griffith JS, Binkley PA, Kirma NB, Schenken RS, Witz CA, Tekmal RR.

Fertil Steril. 2010 Dec;94(7):2531-5. doi: 10.1016/j.fertnstert.2010.04.018. Epub 2010 May 31.


Extranuclear functions of ER impact invasive migration and metastasis by breast cancer cells.

Chakravarty D, Nair SS, Santhamma B, Nair BC, Wang L, Bandyopadhyay A, Agyin JK, Brann D, Sun LZ, Yeh IT, Lee FY, Tekmal RR, Kumar R, Vadlamudi RK.

Cancer Res. 2010 May 15;70(10):4092-101. doi: 10.1158/0008-5472.CAN-09-3834. Epub 2010 May 11.


PELP1 is a reader of histone H3 methylation that facilitates oestrogen receptor-alpha target gene activation by regulating lysine demethylase 1 specificity.

Nair SS, Nair BC, Cortez V, Chakravarty D, Metzger E, Schüle R, Brann DW, Tekmal RR, Vadlamudi RK.

EMBO Rep. 2010 Jun;11(6):438-44. doi: 10.1038/embor.2010.62. Epub 2010 May 7.


Thymoquinone poly (lactide-co-glycolide) nanoparticles exhibit enhanced anti-proliferative, anti-inflammatory, and chemosensitization potential.

Ravindran J, Nair HB, Sung B, Prasad S, Tekmal RR, Aggarwal BB.

Biochem Pharmacol. 2010 Jun 1;79(11):1640-7. doi: 10.1016/j.bcp.2010.01.023. Epub 2010 Jan 25. Retraction in: Biochem Pharmacol. 2016 Feb 15;102:146.


PELP1: A novel therapeutic target for hormonal cancers.

Chakravarty D, Tekmal RR, Vadlamudi RK.

IUBMB Life. 2010 Mar;62(3):162-9. doi: 10.1002/iub.287. Review.


BU-32: a novel proteasome inhibitor for breast cancer.

Agyin JK, Santhamma B, Nair HB, Roy SS, Tekmal RR.

Breast Cancer Res. 2009;11(5):R74. doi: 10.1186/bcr2411.


Regulation of aromatase induction by nuclear receptor coregulator PELP1.

Vadlamudi RK, Rajhans R, Chakravarty D, Nair BC, Nair SS, Evans DB, Chen S, Tekmal RR.

J Steroid Biochem Mol Biol. 2010 Feb 28;118(4-5):211-8. doi: 10.1016/j.jsbmb.2009.09.009. Epub 2009 Sep 30.


Design of curcumin-loaded PLGA nanoparticles formulation with enhanced cellular uptake, and increased bioactivity in vitro and superior bioavailability in vivo.

Anand P, Nair HB, Sung B, Kunnumakkara AB, Yadav VR, Tekmal RR, Aggarwal BB.

Biochem Pharmacol. 2010 Feb 1;79(3):330-8. doi: 10.1016/j.bcp.2009.09.003. Epub 2009 Sep 6. Retraction in: Biochem Pharmacol. 2016 Feb 15;102:143.


Elevated aromatase expression correlates with cervical carcinoma progression.

Veerapaneni P, Kirma N, Nair HB, Hammes LS, Hall KL, Tekmal RR.

Gynecol Oncol. 2009 Sep;114(3):496-500. doi: 10.1016/j.ygyno.2009.05.041. Epub 2009 Jun 24.


Induction of endometrial epithelial cell invasion and c-fms expression by transforming growth factor beta.

Liu YG, Tekmal RR, Binkley PA, Nair HB, Schenken RS, Kirma NB.

Mol Hum Reprod. 2009 Oct;15(10):665-73. doi: 10.1093/molehr/gap043. Epub 2009 Jun 8.


Menstrual endometrial cells from women with endometriosis demonstrate increased adherence to peritoneal cells and increased expression of CD44 splice variants.

Griffith JS, Liu YG, Tekmal RR, Binkley PA, Holden AE, Schenken RS.

Fertil Steril. 2010 Apr;93(6):1745-9. doi: 10.1016/j.fertnstert.2008.12.012. Epub 2009 Feb 6.


A potential role for colony-stimulating factor 1 in the genesis of the early endometriotic lesion.

Jensen JR, Witz CA, Schenken RS, Tekmal RR.

Fertil Steril. 2010 Jan;93(1):251-6. doi: 10.1016/j.fertnstert.2008.09.050. Epub 2008 Nov 6.


Up-regulation of VEGF, c-fms and COX-2 expression correlates with severity of cervical cancer precursor (CIN) lesions and invasive disease.

Hammes LS, Tekmal RR, Naud P, Edelweiss MI, Kirma N, Valente PT, Syrjänen KJ, Cunha-Filho JS.

Gynecol Oncol. 2008 Sep;110(3):445-51. doi: 10.1016/j.ygyno.2008.04.038. Epub 2008 Jun 20.


Supplemental Content

Loading ...
Support Center